Allogeneic double-negative T cells (the drug) express NKG2D; binding to ULBP1 (an NKG2D ligand) on target cells triggers MHC-independent cytotoxic degranulation (perforin/granzyme) and cytokine release, leading to target cell lysis/apoptosis.